[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555524":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":38,"responsibleParty":57,"collaborators":59,"id":63,"slug":11,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of Maryland St. Joseph Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketorolac arm","ACTIVE_COMPARATOR",null,[13],"Drug: Ketorolac Tromethamine",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo Arm","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Ketorolac Tromethamine","IV Ketorolac 15mg every 6 hours, x 4 doses",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","IV saline as placebo",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Aja Janyavula","CONTACT","410-427-5459","ajanyavula@umm.edu",{"name":36,"role":32,"phone":33,"phoneExt":11,"email":37},"Sam Rudow","samuel.rudow@umm.edu",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Towson","Maryland","21204","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-76.60191,39.4015,{"lat":50,"lon":49},[53,54],{"name":36,"role":32,"phone":33,"phoneExt":11,"email":37},{"name":55,"role":56,"phone":11,"phoneExt":11,"email":11},"Justin Tortolani, MD","PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[60],{"name":61,"class":62},"Medical Metrics Diagnostics, Inc","INDUSTRY","100555524",false,"NCT06513208","Ketorolac Effects on Post-operative Pain and Lumbar Fusion","Ketorolac Effects on Post-operative Pain and Lumbar Fusion: a Double Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-85 years old (inclusive)\n* Elective posterior lumbar instrumented fusion\n* One or two level fusion\n* Consent to participate in study and willing to adhere to study follow up\n* English proficiency\n\nExclusion Criteria:\n\n* \\\u003C 18 or \\> 85 years old\n* History of renal failure, dialysis, or creatinine over 1.50 mg\u002Fdl\n* Active or recent smoker (active within past 6 months)\n* Revision surgery\n* Auto\u002Fworker compensation\n* Active cancer or history of chemotherapy in past 6 months\n* Active narcotic use within 3 months of surgery date\n* Infection at operative levels\n* Any allergies to NSAIDs or Opioids",true,"ALL","18 Years","85 Years",{"count":74,"type":75},140,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","A double blind prospective randomized trial of IV ketorolac vs. placebo in management of patients undergoing lumbar one or two level spinal fusions.",[81],"Lumbar Spinal Fusion",[83,84,85],"ketorolac","toradol","lumbar spine fusion","2025-12-18",{"date":88,"type":89},"2025-12-22","ACTUAL",{"date":91,"type":75},"2026-01",{"date":93,"type":75},"2027-06",{"name":5,"class":6},1]